	BC	3	OPV						DPT			DI	PT-He	р В+Н	lib		DPT	+Hib	)	Hep B**				Hib						
													nber of	doses																
Country	1	2	NB§	1	2	3	4	5	6	1	2	3	4	5	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
ARG	NB			2m	4m	6m	18m	6y						6у		,	2009		2m	4m	6m	18m	NB	2m	6m					
BOL*	NB			2m	4m	6m									2m	4m	6m													
BRA*	NB			2m	4m	6m	15m						15m	4-6y					2m	4m	6m		NB	1m	6m					
СНІ	NB			2m	4m	6m	18m						18m	4y	2m	4m	6m													
COL	NB		NB	2m	4m	6m	18m	5у					18m	5у	2m	4m	6m						NB							
COR	NB			2m	4m	6m	4y				4m	15m	4y		2m	6m							NB					4m	15m	
CUB	NB			2 (<1y)	2 (1y)	2 (2y)	1 (9y)						18m	6y*	2m	4m	6m						NB							18m
DOR	NB			2m	4m	6m	18m	4y					18m	4y	2m	4m	6m						NB							
ECU	NB			2m	4m	6m	18m						18m	6y*	2m	4m	6m						NB*	school c	hildren at	-risk				
ELS	NB			2m	4m	6m	15m	4y					15m	4y	2m	4m	6m							risk g	roups					
GUT	NB			2m	4m	6m	18m	4y					18m	4y	2m	4m	6m													
HAI	NB		NB	6w	10w	14w	+1y			6w	10w	14w	+1y																	
HON	NB			2m	4m	6m	1-4y						18m	4-5y	2m	4m	6m						NB	ris	k groups					
MEX*	NB			*	*	*							2у	4y	2m*	4m*	6m*						NB	2m	6m	12y+				
NIC	NB			2m	4m	6m	*						18m		2m	4m	6m							health v						
PAN	NB			2m	4m	6m	18m	4-5y						4-5y	2m	4m	6m					18m	NB		orkers at i children at					
PAR	NB			2m	4m	6m	18m	4y					18m	4y	2m	4m	6m					_		risk g						
PER	NB			2m	4m	6m							18m	4y	2m	4m	6m						NB		ation at ris	sk				
URU	NB			2m	4m	6m	12m							5у	2m	4m		15m					12y	+1m	+6m					
VEN	NB	. d in	NB	2m	4m	6m							18m		2m	4m	6m						NB	ris	k groups					

text bold and in red are still pending replies

### NB: Newborn

WCBA(s): Women of Childbearing Age

- \*\* This table only includes the hepatitis B vaccine used in children national schedules. Vaccination of at-risk groups is not included.
- \*\*\* TT/dT use reported as indicated by countries in the EPI Indicator Tables.
- § Doses administered to newborns do not count towards the completion of the primary series.
- \* BOL: Hepatitis B for newborns only in selected hospitals.
- \* CUB: DT pediatric administered at 6 years; vaccine used is tetravalent DPT+Hep B (starting in 2005).
- \* ECU: DT 2nd booster given to 2nd and 7th graders; HepB given to newborns in municipalities at risk; DT pediatric administered at 6 years
- \* HON OPV NB dose removed from schedule in 2006
- \* MEX: OPV doses for children 6 months to 5 years old during National Health Weeks; Pentacel (DTaP-Hib-IPV) given
- \* NIC: Additional OPV doses for children during National Health Weeks.






	M MMR				MR			TT/dT***			Yellow Fever†	Influenza		Varicella	Hepat	titis A	
									Numbe	er of Doses				10.100110			
Country	1	1	2	3	1	1	2	3	4	5	1	1	2	1	1	2	
ARG		1y	6y		MEF	16y		ever	y 10y		≥1y in population	risk groups; ≥65y		risk groups	12m		
											in border areas			starting 2009			
BOL*		12-23m				WCBAs	WCBAs	WCBAs	WCBAs	WCBAs	12-23m						
BRA*		1y	4-6y		WCBAs	>7y	WCBAs				9m; 10y	≥60y; risk groups		indigenous populations	spe gro	ecial ups	
СНІ		1y	6y			7y						risk groups; ≥60y; pregnant women; health workers					
COL		1y	5у				WCBAs			1y; population in atrisk areas;	6m-23m (2 doses); ≥65y in some districts						
COR		15m	7у			10y		ever	y 10y			risk groups; 6m to <8y with risk factors; ≥65y		risk groups; 15m			
CUB		1y	6y			15y*						≥65y; children <24m w/chronic diseases					
DOR		1y				WCBAs	WCBAs	WCBAs				>65y; persons w/chronic diseases					
ECU		12-23m			6y	11y	WCBAs			>1y at risk areas	6-23m ; ≥65y						
ELS		1y	4y			<u>≥</u> 10y		ever pregnan	y 10y t women			risk groups; 6m-23m; >60y					
GUT		1y						WCBAs				>60y					
HAI					9m			WCBAs									
HON		1y			susceptibles	11-12y		WC				6-23m with chronic diseases; risk groups; >60y					
MEX*		1y	6y			11-12y (Grade 6)	WCBAs	WCBAs	WCBAs	WCBAs		6m-35m; ≥60y and risk groups		immunocompromis ed 1y (social security)			
NIC		1y				6-9y	10-14y		MEF			6-23m; >65y with chronic disease					
PAN		1y	4-5y			6у	MEF				>1y in population at-risk	6m-23m, >60y; risk groups			12m	18m	
PAR		1y	4y		5y-39y	WCBAs	WCBAs	WCBAs	WCBAs	WCBAs	≥1y in population in border areas	6-23m; >60; other risk groups					
PER		1y	4y			WCBAs	WCBAs	WCBAs	WCBAs	WCBAs	1y	risk groups					
URU		1у	5у			12y	every 10y				risk groups; 6-23m; ≥65y		1y	15m	21m		
VEN		1y				WCBAs	WCBAs	WCBAs	WCBAs	WCBAs	>1y*	≥65y; risk grou	ps				

NB: Newborn

WCBA(s): Women of Childbearing Age

- § Doses administered to newborns do not count towards the completion of the primary series.
- † Yellow Fever vaccine administered to travellers to endemic countries not included
- \* DOR: Influenza given to >60 year olds in retirement homes
- \* PAN: Introduced Hepatitis A vaccines in May 2006 and rotavirus vaccine in Feb 2006.
- \* VEN: Yellow fever vaccine administered to population in at-risk municipalities, in addition to recruits and travelers to endemic areas.
- \* CUB: TT only






	Rotavi	rus		Vitamin A										Pneumo		Meningitis BC					
	110101				Numbe	er of D		2	-												
Country	1	2		1	2	3	4	5				6	1	2	3	4	5	1	2		
ARG																					
													risk groups								
BOL*	2m	4m		6-11m	1-4y																
BRA*	2000	4m											2m*	4m*	6m*	h t 40 45*		booster 12-15m*			
CHI	2m	4111											2111	4111	OIII	DOOSIEI	12-13111				
OI II																					
COL		1											Heptaval	ente (April 2	2008); given	to populati	on at risk				
	to popula	ation a	t risk											` '	,. •						
	Apri	1 2008																			
COR																					
													2m	4m	6m	15m					
CUB													2111	4111	OIII	13111					
002																					
																		3m	5m		
DOR																					
				6m	12m	18m															
ECU	2m	4m		6m	12m	18m	24m	30m	36m												
ELS																					
GUT	2m	4m		6m	12m	18m	2450	20	26	4000	40.00	E 4 ma									
HAI				0111	12111	10111		n-7y	30111	42111	40111	54111									
HON				6m	12m	18m	24m	30m	36m												
				0				00	00												
	intro in	feb 20	009																		
MEX*																					
	2m	4	m	NB	6-5	9m							2m	4m	12m						
NIC	2m	100	Con	Com	4.,	211	211	457					0	400	Com	(intr-	~ 2000)				
PAN	2m	4m 4m	6m	6m 6m	1y 12m	2y 18m	Зу	4y					2m	4m	6m	(Intro II	n 2009)				
FAN	2111	4111		OIII	12111	10111							2m*	4m*	6m*	12-1	15m*				
PAR													2111		OIII	1,2					
PER		4m*	6m*	6m	12m	23m							2m*	4m*	6m*						
URU																					
1/51	0	4											2m	4m	12m						
VEN	2m	4m																			

NB: Newborn

WCBA(s): Women of Childbearing Age

- § Doses administered to newborns do not count towards the completion of the primary series.
- \* ARG: Tdap will be administered to health workers starting in 2009; Argentinian hemorrhagic fever for groups at risk
- \* BRA: Pneumo\_conj given to population at risk
- \* ECU: Rotavirus introduced in October 2007
- \* MEX: Rotavirus will be extended in the national level; SNS-Semana Nacional de Salud; Pneumo\_conj given subnationally, to be scaled up in 2008
- \* PAN: in population at risk
- \*PER: At subnational





	T	yphoid Fev	er	Tdap	Pneumo_Polysaccharide	HPV
	,				· · · · · · · · · · · · · · · · · · ·	
Country	1	2	3	1	1	1
ARG	armed f	orces startii	ng 2009	11a*	risk groups	11a
BOL*					-	
BRA*		risk groups			risk groups	
СНІ					65y+	
COL						
COR				?		
CUB	10y	13y	16y			
DOR	TOY	109	loy			
ECU					older adults	
ELS						
GUT						
HAI						
HON						
MEX*					≥65y	12y; risk municipalities*
NIC						
PAN				11y		10y (3 doses)
PAR						
PER						3 doses*
URU						
VEN						



<sup>\*</sup> MEX: will be given nationwide in 2009

<sup>\*</sup> PER: at subnational level